Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 | P07550 | 18/20 | 0.80 |
| ▸ | ADRB1 | P08588 | 4/20 | 0.80 |
| ▸ | DRD2 | P14416 | 3/20 | 0.80 |
| ▸ | ABCB11 | O95342 | 2/20 | 0.80 |
| ▸ | PDE4A | P27815 | 1/20 | 0.80 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL5380522 | 0.99 | ADRB2 (0.78) | ADRB2ADRB1DRD2ABCB11PDE4A | |
| SCHEMBL8527857 | 0.96 | ADRB2 (0.78) | ADRB2ADRB1DRD2ABCB11PDE4A | |
| Hydrochloric Acid SCHEMBL8528391 | 0.95 | ADRB2 (0.76) | ADRB2ADRB1DRD2ABCB11PDE4A | |
| SCHEMBL8529299 | 0.94 | ABCB11 (0.83) | ADRB2ADRB1DRD2ABCB11PDE4A | |
| SCHEMBL7837102 | 0.94 | ABCB11 (0.83) | ADRB2ADRB1DRD2ABCB11PDE4A | |
| Hydrochloric Acid SCHEMBL8533675 | 0.93 | ABCB11 (0.81) | ADRB2ADRB1DRD2ABCB11PDE4A | |
| SCHEMBL7836415 | 0.93 | ABCB11 (0.81) | ADRB2ADRB1DRD2ABCB11PDE4A | |
| SCHEMBL7828832 | 0.93 | ABCB11 (0.81) | ADRB2ADRB1DRD2ABCB11PDE4A | |
| Hydrochloric Acid SCHEMBL7838099 | 0.93 | ABCB11 (0.81) | ADRB2ADRB1DRD2ABCB11PDE4A | |
| SCHEMBL7840400 | 0.93 | ABCB11 (0.81) | ADRB2ADRB1DRD2ABCB11PDE4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7163672-B2 | Pharmaceutical aerosol formulation | ASTRAZENECA AB (SE) | 2007-01-16 | — | — | US | claimed |
| EP-1345591-B1 | PHARMACEUTICAL AEROSOL FORMULATION | ASTRAZENECA AB (SE) | 2005-03-02 | — | — | EP | claimed |
| US-20040082520-A1 | Pharmaceutical aerosol formulation | ASTRAZENECA AB (SE) | 2004-04-29 | — | — | US | claimed |
| EP-1345591-A1 | PHARMACEUTICAL AEROSOL FORMULATION | AstraZeneca AB (SE) | 2003-09-24 | — | — | EP | claimed |
| WO-2002049616-A1 | PHARMACEUTICAL AEROSOL FORMULATION | ASTRAZENECA AB (SE) | 2002-06-27 | — | — | WO | claimed |
| EP-0649418-B1 | 7-(2-AMINOETHYL)-BENZOTHIAZOLONES | ASTRA PHARMA PROD (GB) | 1998-10-28 | — | — | EP | claimed |
| US-5648370-A | 7-(2-aminoethyl) benzothiazolones | ASTRA PHARMACEUTICALS LIMITED (GB) | 1997-07-15 | — | — | US | claimed |
| EP-0649418-A1 | 7-(2-AMINOETHYL)-BENZOTHIAZOLONES | Astra Pharmaceuticals Limited (GB) | 1995-04-26 | — | — | EP | claimed |
| WO-1993024473-A1 | 7-(2-AMINOETHYL)-BENZOTHIAZOLONES | FISONS PLC (GB) | 1993-12-09 | — | — | WO | claimed |
| US-7163672-B2 | Pharmaceutical aerosol formulation | ASTRAZENECA AB (SE) | 2007-01-16 | — | — | US | disclosed |
| US-20050222193-A1 | Novel combination for the treatment of airway disorders | ALTANA PHARMA AG (DE) | 2005-10-06 | — | — | US | disclosed |
| WO-2005074932-A1 | THE USE OF (S) - PANTOPRAZOLE MAGNESIUM FOR THE TREATMENT OF AIRWAY DISORDERS | ALTANA PHARMA AG (DE) | 2005-08-18 | — | — | WO | disclosed |
| US-20050165041-A1 | Combination for the treatment of airway disorders | ALTANA PHARMA AG (DE) | 2005-07-28 | — | — | US | disclosed |
| EP-1517706-A2 | COMBINATION OF A PROTON PUMP INHIBITOR AND A RESPIRATORY AGENT FOR THE TREATMENT OF RESPIRATORY DISEASES | ALTANA Pharma AG (DE) | 2005-03-30 | — | — | EP | disclosed |
| EP-1345591-B1 | PHARMACEUTICAL AEROSOL FORMULATION | ASTRAZENECA AB (SE) | 2005-03-02 | — | — | EP | disclosed |
| EP-1506016-A2 | NEW COMBINATION OF REVERSIBLE PROTON PUMP INHIBITORS AND AIRWAY THERAPEUTICS FOR TREATING AIRWAY DISORDERS | ALTANA Pharma AG (DE) | 2005-02-16 | — | — | EP | disclosed |
| US-20040082520-A1 | Pharmaceutical aerosol formulation | ASTRAZENECA AB (SE) | 2004-04-29 | — | — | US | disclosed |
| WO-2003094967-A2 | NEW COMBINATION OF REVERSIBLE PROTON PUMP INHIBITORS AND AIRWAY THERAPEUTICS FOR TREATING AIRWAY DISORDERS | ALTANA PHARMA AG (DE) | 2003-11-20 | — | — | WO | disclosed |
| WO-2003094968-A2 | COMBINATION OF A PROTON PUMP INHIBITOR AND A RESPIRATORY AGENT FOR THE TREATMENT OF RESPIRATORY DISEASES | ALTANA PHARMA AG (DE) | 2003-11-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040082520-A1 | Pharmaceutical aerosol formulation | ALG1, ALG8, DDOST | ADRB2 64/4885ADRB1 65/4885DRD2 400/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.